
TL;DR
Lab claim denials often begin at order entry, not billing. Toxicology, pharmacogenomics (PGx), and molecular claims face different payer requirements involving medical necessity, prior authorization, eligibility, documentation, and coding. This guide compares denial causes across Medicare, Medicaid, commercial payers, and client billing, explains underpayments and write-offs, and outlines pre-billing checks and a quarterly audit process to help laboratories prevent revenue leakage.
A denied lab claim has one cruel feature: the test already happened. The reagent is spent, the tech has moved on, the report went out on time, and now a payer wants a diagnosis code nobody asked for at the front desk. Sort your list of lab claim denials by test category and see whether toxicology, pharmacogenomics (PGx) and molecular sit near the top. If they do, each is probably failing for a different reason, and each reason lives in a different payer’s rulebook.
The common thread is timing. Most of these denials are created at order entry, weeks before anyone builds the claim. This guide breaks down the causes by test category and payer, covers the money that leaves without ever showing up as a denial, and gives you a check for each cause. For the general recovery process, start with CrelioHealth’s guide to lab revenue cycle management; this post goes narrower and deeper.
Billing teams inherit denials the way a night shift inherits a backed-up batch. They did not create the mess, but they get to clear it. In a January 2026 MLO Online interview, Roshan Patel of Arrow, an AI revenue cycle company, argued that the test itself is rarely the problem. The paperwork around it is, and small errors repeated across high volumes cause most of the losses. That is one vendor’s view, but it matches what you see when you follow a single order from start to finish.
Here is where each problem can enter:
| Step in the order path | What can go wrong | How it shows up later |
|---|---|---|
| Requisition | Missing diagnosis, unclear test selection, incomplete ordering information | Medical necessity or documentation denial |
| Diagnosis and test codes | A diagnosis that does not support the test ordered; codes that do not match the panel | Coding or medical necessity denial |
| Eligibility | Coverage inactive, or the wrong payer on the date of service | Eligibility denial |
| Accessioning | Specimen or requisition details that do not match the order | Documentation problem and rework |
| Claim | Everything above, plus filing after the payer's window closes | Timely filing denial |
Fixing a denial at the billing desk is rework. Someone has to find the requisition, call the ordering office, correct the record, and resubmit. At order entry, the same fix is one question to the front desk. The cause sits upstream; only the symptom arrives with the remittance. If paper and faxed requisitions still feed your front desk, CrelioHealth’s post on AI-based requisition scanning shows how that data can be captured at accessioning instead of retyped.
Six causes families run through the rest of this post:
Your payer mix decides where the effort goes. A lab that is mostly Medicare fights different battles from one that bills referring facilities directly, and a lab revenue cycle payer analysis by payer type, not just by payer name, shows which checks to build first. Payer mix denials rarely look alike even when the remittance codes do.
| Payer type | What it typically checks | Typical way a lab claim fails |
|---|---|---|
| Medicare | Coverage rules in national and local coverage determinations (NCDs and LCDs); diagnosis codes that support the test; a valid ABN where coverage is limited; filing within 12 months of the date of service | Diagnosis does not support the test under the LCD; ABN missing for a limited-coverage test; claim filed after the 12-month limit |
| Medicaid | State program rules, including prior approval or service limits where a state sets them | Authorization missing or not matched to the ordered test; service limits exceeded |
| Commercial | The plan's own medical policy, authorization requirements and contracted rates | Policy criteria not met; authorization not on file; claim paid below the contracted rate |
| Client bill (a lab billing a referring facility directly) | The price list and billing instructions agreed with the client | Panel or test billed does not match what the client ordered or contracted; wrong billing account |
Medicare publishes the most public rulebook, so it is the easiest place to start. Its claims manual sets a 12-month window from the date of service, and Noridian notes that a claim denied for timely filing has no appeal rights. Where coverage is limited, Medicare expects an Advance Beneficiary Notice (ABN) before the test runs; the CMS ABN page explains who issues it, and it also shows that OMB approved a refreshed CMS-R-131 form in March 2026, so check the version your front desk is using.
Medicaid and commercial rules are less tidy. KFF’s state-by-state survey of Medicaid lab benefits shows that prior approval and service limits differ across states, and commercial plans set their own policies. The Medicare row above rests on published CMS policy. The other rows describe common failure points, and your own contracts have the final word, so read them before you build a single rule.
Tox, PGx and molecular claims are denied mainly for medical necessity gaps, missing or mismatched prior authorization, and documentation or coding errors that were visible at order entry. The matrix below puts each test category against each payer type and names the main cause in each cell.
| Test category | Medicare | Medicaid | Commercial | Client bill |
|---|---|---|---|---|
| Toxicology | Medical necessity for definitive testing | Service limits and authorization, by state | Plan policy on presumptive versus definitive; authorization | Panel billed differs from panel ordered |
| PGx | Limited coverage; clinical context not documented | State authorization, where required | Prior authorization and plan policy | Panel not on the client price list |
| Molecular | Documentation, test identifiers and panel coding | State coverage and authorization | Prior authorization; bundling of panel components | Panel or price mismatch against the contract |
Treat the Medicare column as sourced from published policy and the other three as starting hypotheses to test against your own denial data. A matrix like this earns its keep when you overwrite these guesses with your own numbers.
Each cause in plain terms:
Toxicology claims turn on a distinction the order has to carry: presumptive versus definitive testing. Medicare’s urine drug testing policy defines presumptive testing as a qualitative check for the presence of drugs or drug classes, and definitive testing as identification of specific medications, illicit substances and metabolites. One contractor’s clinician checklist says the documentation must support why a definitive test was ordered instead of a presumptive one. Coverage policies differ by contractor, so confirm the version your MAC publishes.
That turns the order-entry question into something concrete: does the order say why this patient needs definitive testing, in words the payer’s policy recognizes? If the clinical reason lives only in the chart at the practice, you find out when a medical necessity denial lands on the remittance. For the bench side of screening and confirmation, see CrelioHealth’s post on dedicated pain management lab workflows.
PGx is a coverage puzzle before it is a billing one. The Medicare MolDX policy for pharmacogenomics testing is a limited coverage policy that applies to single-gene tests, multi-gene panels and combinatorial tests. An earlier published version describes PGx as reasonable and necessary only in limited circumstances, as a decision tool once the treating clinician has narrowed treatment options to specific medications. Confirm the current version with your contractor.
There is also a trap in the numbering. The same MolDX policy appears under different LCD numbers depending on the contractor: Noridian, for example, lists L38337 for its Jurisdiction F states and L38335 for Jurisdiction E. Find the one that applies to your MAC before you write a rule. Commercial plans and state Medicaid programs add policies and prior authorization steps of their own, so the practical goal is the same everywhere: the order should show which medication decision the test supports before the specimen is run.
Molecular claims add two more failure points: test identification and panel coding. CMS’s billing and coding article for MolDX molecular tests describes entering a DEX Z-Code in a defined field of the Part B claim, and reminds readers that Section 1833(e) of the Social Security Act bars Medicare payment for claims that lack the necessary documentation. For panels, Chapter 16 of the Medicare Claims Processing Manual includes a section on evaluating medical necessity for laboratory panel CPT codes. In practice, the CPT code, the test identifier and the ordered panel all have to agree before the claim is built.
Prior authorization is the other half. CrelioHealth’s lab RCM guide frames molecular diagnostics as a prior authorization and test-specific identifier problem, with the control being confirmation of authorization before the specimen runs. For prior authorization in molecular testing, the practical rule is blunt: if the authorization is not on the order when the specimen arrives, treat it as an open exception today, not a billing question next month. Requirements vary by payer, so check each contract.
Find the row and column your lab bills most, and start your audit in that cell. A lab built around commercial molecular volume should start somewhere different from one built around Medicare toxicology. One cell, one cause, one check: that is a small enough project to finish.
A denial report counts only the claims someone said no to. Two other kinds of loss never appear on it, and both are quiet enough to survive a good quarter.
An underpayment is a claim that is paid, but below the contracted or expected rate. It never shows up on a denial report because the payer approved it. Finding lab billing underpayments takes a comparison: paid amount against expected rate, by payer and by test.
For Medicare, the expected rate is public. CMS pays most clinical lab tests at the weighted median of private payer rates, with updates generally every three years. CMS lists no phase-in reduction for 2026, and then reductions capped at 15% a year compared with the prior year from 2027 through 2029. Here is a simple illustration, not a published figure: take a test that paid $100 in 2026. A 15% cut puts it at $85. If your system still expects $100, every correct payment looks like a $15 shortfall, and a real shortfall hides inside the noise.
Signals worth watching:
When variance shows up, fee schedule loads, contract terms, and bundling rules are the usual places to look first.
Lab write-offs come in three kinds, and each has a signal a billing lead can watch.
| Kind of write-off | How it happens | Signal to watch |
|---|---|---|
| Timely-filing misses | Orders sit unbilled, waiting on missing information, until the payer's window closes. Medicare allows 12 months and offers no appeal for a late filing; other payers set their own windows. | Aging of unbilled orders against each payer's filing window |
| Small-balance write-offs | Balances under an internal threshold are closed automatically, so repeated low-dollar errors never get a second look. | Count and total of small write-offs by payer and test, not just by size |
| Denials nobody worked | Denials sit in a queue, worked in arrival order or not at all. | Share of denials with no action by age, ranked by dollars |
None of these needs new data to detect. They need someone to look at the data you already have, which is the whole point of the audit later in this post.
Every cause so far has a matching check, and every check runs earlier than most billing teams look. This table is a summary; the full set of order-entry checks lives in CrelioHealth’s denial prevention checklist, so it is not repeated here.
| Cause | Check | Runs at |
|---|---|---|
| Medical necessity | Compare each ordered test's diagnosis with the payer's coverage policy before the order is accepted. | Order entry |
| Prior authorization | Confirm an authorization is on file and covers the ordered test, panel and date. | Order entry |
| Eligibility | Verify active coverage and the correct payer for the date of service. | Order entry |
| ABN (Original Medicare) | Where coverage is limited, obtain the current CMS-R-131 before the specimen is run. | Order entry or collection |
| Documentation | Confirm the clinical reason for definitive, PGx or molecular testing is on the order. | Accessioning |
| Coding and bundling | Confirm CPT codes, panel codes and test identifiers agree with what was ordered. | Pre-claim |
| Timely filing | Alert on unbilled orders as they age toward the payer's filing window. | Pre-claim |
| Underpayment | Compare each payment with the expected rate for that payer and test. | Payment posting |
Notice how many land at the first stage. A missing diagnosis at order entry is a question the front desk can answer in thirty seconds. Three weeks later it is an appeal. That is why denial prevention in lab billing works best at order entry, and why CrelioHealth’s LIMS handles insurance eligibility verification and pre-authorization capture at ordering, as covered in its Q1 2025 product update.
A quarterly lab billing audit traces denied and underpaid claims back to their cause, then fixes the highest-dollar cause first. Six steps:
A quarter is short enough to catch unbilled or rejected claims well before Medicare’s 12-month window closes, and long enough to show a pattern. Step four matters most. A cause that is half your denials by count can be a small share of your dollars, and the reverse is just as common.
The checks above run earlier than most billing systems look. Revenue Guard is CrelioHealth’s pre-billing order check: it reads each order against your payer rules before billing, while a problem is still an edit and not an appeal.
Here is what that looks like in practice:
A rule is only as good as the policy behind it, which is why the audit comes first. Take the top cause from your matrix, turn it into a rule, and run a batch of recent orders through it to see what it would have caught. The 14-day free trial, which needs no credit card, is a practical way to do exactly that. If faxed or scanned requisitions are where your bad data starts, AiReq reads them into structured orders your team approves, and Revenue Guard then checks those orders.
If you are comparing billing platforms rather than testing one workflow, CrelioHealth’s buyer’s guide for laboratory billing software covers how to evaluate them. When you are ready to test the order-entry approach on your own claims, start a Revenue Guard 14-day trial.
Most lab claim denials trace to six causes: medical necessity, prior authorization, coverage and eligibility, coding and bundling, documentation gaps, and missed filing windows. Each usually enters at order entry or accessioning, long before the claim is built, which is why the cheapest fix sits at the front end.
Each depends on payer policy that must be satisfied at order entry. Toxicology turns on documenting why definitive testing was needed. PGx turns on limited coverage and clinical context. Molecular turns on authorization, test identifiers, and panel coding. Missing any one of those usually means a denial.
A denial means the payer refused to pay a claim. An underpayment means the payer paid, but less than the contracted or expected rate. Denials appear on a denial report, and underpayments do not, so a lab needs a paid-versus-expected comparison by payer and test to find them.
Run checks at order entry: verify eligibility, match the diagnosis to the payer’s coverage policy, confirm authorization, obtain an ABN where Medicare coverage is limited, and capture the clinical reason for specialty tests. Then check codes before the claim is built. Fixing an order takes minutes; fixing a denial takes a rework cycle.
Quarterly works for most labs. It is long enough to show patterns and short enough to fix causes before filing windows close. Pull denied and underpaid claims, sort by test category and payer, rank causes by dollars, apply the matching check, and rerun next quarter to measure the change.
A denial is a question the front desk could have asked, delivered three weeks late. The matrix shows you where yours come from, and the checks show you when to ask. This week, pick the test category and payer type that make up most of your volume, pull last quarter’s denied and underpaid claims for that one cell, and name the top cause. If you want the wider process around that audit, the lab RCM guide walks through it. And when you want to see order-entry checks run against your own claims, start a Revenue Guard 14-day trial.